Welcome to a dedicated resource to help healthcare professionals find the latest information on the symptoms and diagnosis of multiple myeloma, measuring treatment response and research into new classes of treatment.

What is multiple myeloma

Multiple myeloma is a clonal plasma cell proliferative disorder, characterised by hypercalcaemia, renal failure, anaemia and bone lesions.1 It is more common in older adults, although about one-third of patients are younger than 65 years of age at diagnosis.2 

Multiple myeloma is a challenging disease to manage that becomes more difficult to treat as it progresses.3 Due to its heterogeneous nature, patients will present with different symptoms and clinical courses.3 However, guidelines for treatment are available to help you offer your patients the best option for them at each step of their multiple myeloma journey.3

Recent advances in the understanding of the biology of the disease, enhanced diagnostic criteria, developments in supportive care and the introduction of more effective treatment strategies have all led to improvements in patient outcomes. In the future, more sensitive measures of depth of response may prove useful in predicting treatment outcomes and possibly in guiding treatment.4

Understanding Multiple Myeloma

Even with significant advances in treatment, myeloma remains a challenging disease. Find out more about this type of cancer and its pathophysiology.
Learn more

Explore Multiple Myeloma

Focusing on Diagnosis

There are a range of diagnostic methods that can generate an in-depth picture of the patient’s myeloma characteristics. Early detection is paramount in disease management and in determining a treatment plan.


Diagnostic options

Improving Patient Outcomes

Getting the treatment plan right can improve your patient’s outcomes. Explore how treatment response is measured and what strides are being taken to optimise treatment response.



Treating Multiple Myeloma

Besides alleviating symptoms and complications, the aim of treatment is to extend and improve the patient’s quality of life.


Learn more

Emerging Targets

Despite treatment progress with novel therapies such as proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, there remains an unmet clinical need for effective therapies.




  1. Rajkumar S et al. Lancet Oncol  2014; 15(12):e538–e548.
  2. Howlader N et al. SEER Cancer Statistics Review, 1975–2017. Available at: https://seer.cancer.gov/csr/1975_2017/results_single/sect_01_table.04_2p... (last accessed August 2020).
  3. Moreau P et al. Ann Oncol  2017; 28(Suppl_4):iv52–iv61.
  4. Lahuerta JJ et al. J Clin Oncol  2017; 35(25):2900–2910.

ITEM CODE: CP-179624 | DATE OF PREPARATION: October 2020